Episode Details
Our Guest: Greg Flesher, President and CEO of Reneo Pharmaceuticals
- What you’ll get out of this episode:
- Greg’s Background Overview of Reneo Pharmaceuticals
- What are the specific rare diseases you are targeting? How does it manifest in patients?
- Detials about his lead candidate mavodelpar and how it helps patients with PMM?
- The latest updates in Reneo’s clinical trial and when you expect to have data?
- What’s next?
Watch
Listen
Read
Introduction
Welcome to our latest interview on cutting edge of medical innovations. Today, we are thrilled to have Greg Flesher, the CEO of Reneo Pharmaceuticals, with us to discuss their groundbreaking work in the field of rare disease treatment. Join us as we explore Greg’s background, the focus of Reneo Pharmaceuticals, and their lead candidate, Mavodelpar.
Greg Flesher’s Journey and the Birth of Reneo Pharmaceuticals
Greg Flesher, a seasoned drug developer with over 28 years of industry experience, takes us on a journey through his career, starting from his early days at Eli Lilly. The impactful experience of working at a company dedicated to patient well-being and drug development set the tone for his future endeavors. Greg’s passion for making a difference led him to the helm of Reneo Pharmaceuticals, an emerging pharmaceutical company focusing on rare diseases.
The Vision and Mission of Reneo Pharmaceuticals
Reneo Pharmaceuticals is on a mission to develop innovative treatments for rare diseases. Greg shares their commitment to addressing unmet medical needs and improving the lives of patients affected by these conditions. The company’s current focus lies in mitochondrial diseases, which affect cellular energy production and can lead to severe symptoms in various organs and tissues.
Introducing Mavodelpar: A Promising Lead Candidate
Greg introduces us to Mavodelpar, Reneo Pharmaceuticals’ lead candidate, which targets primary mitochondrial myopathy—a heterogeneous group of gene defects affecting mitochondrial function. Mavodelpar, a novel chemical entity, acts as a PPAR Delta agonist, enhancing fat metabolism to overcome the energy deficiency observed in patients with mitochondrial diseases. This innovative approach holds great promise for transforming the lives of patients.
Updates on Clinical Trials and Future Prospects
Greg provides exciting updates on the progress of Reneo Pharmaceuticals’ clinical trials. Having completed their early proof of concept studies with outstanding results, the company has now initiated a pivotal trial encompassing multiple trial sites across the globe. The enrollment phase has recently concluded, and data analysis is expected by the end of the year. If the data confirms the positive outcomes observed in earlier stages, Reneo Pharmaceuticals plans to file for regulatory approvals and make their treatment option available to patients in need.
Beyond the Horizon: A Vision for the Future
Greg outlines the long-term goals of Reneo Pharmaceuticals, aiming to become a self-sustaining company that funds its own research and development. With plans to explore additional indications for Mavodelpar and leverage their library of compounds, Reneo Pharmaceuticals envisions a future where their innovative therapies bring hope and relief to a broader range of patients.
WORD FROM OUR SPONSORS:
Our sponsors for this episode are Sage Growth Partners, FlipMD by GoodRX and Quantum Health
Sage Growth Partners accelerates commercial success for healthcare organizations through a singular focus on growth. The company helps its clients thrive amid the complexities of a rapidly changing marketplace with deep domain expertise and an integrated application of research, strategy, and marketing. For more information, please go to www.sage-growth.com & follow Sage Growth Partners on social media – @sagegrowthpartners
GoodRx is a company that operates a platform and mobile application providing information and discounts on prescription drugs. It was founded in 2011 with the aim of helping consumers save money on their medication costs. GoodRx acts as a bridge between consumers, pharmacies, and pharmaceutical companies.
The primary function of GoodRx is to aggregate and compare prices of prescription drugs from various pharmacies across the United States. They gather pricing information for both generic and brand-name medications, allowing users to find the most affordable options available to them. The platform provides users with details about drug prices, discounts, and savings opportunities at different pharmacies in their local area.
For more information, please go to https://www.goodrx.com/ & follow FlipMD on social media – @goodrx
Quantum Health is an award-winning consumer healthcare navigation company that delivers an unparalleled consumer experience based on empathy and trust, enabling employers to achieve industry-leading satisfaction rates and independently validated claim savings. Launched in 1999, Quantum Health’s model is based on years of consumer research and the insights learned from guiding millions of consumers and their providers through their healthcare journey. Visit: https://quantum-health.com/ and follow Quantum health on social media – @Quantum Health
To learn more about Reneo Pharmaceuticals please use the links below:
– Reneo Pharmaceuticals LinkedIn – Reneo Pharmaceuticals Website –
Also, be sure to follow Slice of Healthcare on our social channels:
– Website – LinkedIn – Twitter – YouTube – Newsletter –
